EP 2238105 B1 20140416 - NOVEL COMPOUNDS AS VANILLOID RECEPTOR ANTAGONISTS
Title (en)
NOVEL COMPOUNDS AS VANILLOID RECEPTOR ANTAGONISTS
Title (de)
NEUARTIGE VERBINDUNGEN, ISOMER DARAUS ODER PHARMAZEUTISCH AKZEPTABLE SALZE DAVON ALS VANILLOID-REZEPTORANTAGONISTEN SOWIE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN DAMIT
Title (fr)
NOUVEAUX COMPOSÉS, ISOMÈRE OU SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CES DERNIERS, UTILISÉS COMME ANTAGONISTES DU RÉCEPTEUR VANILLOÏDE, ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
Publication
Application
Priority
- KR 2009000407 W 20090128
- EP 08001555 A 20080128
- EP 09706694 A 20090128
Abstract (en)
[origin: WO2009096701A2] This present disclosure relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present disclosure also provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.
IPC 8 full level
C07C 311/08 (2006.01); C07C 311/13 (2006.01); C07C 311/35 (2006.01); C07C 311/45 (2006.01); C07D 295/145 (2006.01)
CPC (source: EP KR US)
A61K 31/18 (2013.01 - KR); A61P 1/02 (2017.12 - EP); A61P 1/04 (2017.12 - EP); A61P 1/08 (2017.12 - EP); A61P 1/12 (2017.12 - EP); A61P 1/18 (2017.12 - EP); A61P 3/10 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 11/00 (2017.12 - EP); A61P 11/02 (2017.12 - EP); A61P 11/06 (2017.12 - EP); A61P 11/14 (2017.12 - EP); A61P 13/00 (2017.12 - EP); A61P 13/02 (2017.12 - EP); A61P 13/10 (2017.12 - EP); A61P 17/00 (2017.12 - EP); A61P 17/04 (2017.12 - EP); A61P 17/06 (2017.12 - EP); A61P 17/14 (2017.12 - EP); A61P 19/02 (2017.12 - EP); A61P 21/00 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 25/04 (2017.12 - EP); A61P 25/06 (2017.12 - EP); A61P 25/28 (2017.12 - EP); A61P 27/02 (2017.12 - EP); A61P 27/16 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 29/02 (2017.12 - EP); A61P 31/18 (2017.12 - EP); A61P 37/08 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07C 311/08 (2013.01 - EP US); C07C 311/13 (2013.01 - KR); C07C 311/45 (2013.01 - KR); C07D 295/145 (2013.01 - EP US); C07C 2601/14 (2017.04 - EP US)
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR
DOCDB simple family (publication)
WO 2009096701 A2 20090806; WO 2009096701 A3 20090924; CN 101925575 A 20101222; CN 101925575 B 20140618; EP 2238105 A2 20101013; EP 2238105 A4 20120222; EP 2238105 B1 20140416; JP 2011510924 A 20110407; JP 5643112 B2 20141217; KR 101619341 B1 20160511; KR 20100119757 A 20101110; US 2011015230 A1 20110120; US 2014011881 A1 20140109; US 8557872 B2 20131015
DOCDB simple family (application)
KR 2009000407 W 20090128; CN 200980103367 A 20090128; EP 09706694 A 20090128; JP 2010544237 A 20090128; KR 20107016895 A 20090128; US 201314022789 A 20130910; US 86508209 A 20090128